The SELECT Trial: Design and Key Findings The SELECT trial enrolled 17,604 patients aged 45 or older with a BMI of 27 or greater and established cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral artery disease), but critically, none had diabetes .[1] This design was intentionalresearchers wanted to understand whether semaglutide's cardiovascular benefits extended beyond its known effects in diabetic populations
Broad EM, et al
Fibrosis Improvement Without Worsening of MASH - Placebo: 32.8% saw a 1-stage or greater improvement in fibrosis
Proper technique involves cleaning injection site with alcohol swab (let dry), pinching skin fold between fingers, inserting needle at 45-90 degree angle depending on subcutaneous fat amount, injecting slowly and steadily, and disposing properly in sharps container
At 24 weeks, weight reductions ranged from 7.2% with the 1 mg dose to 17.5% with the 12 mg dose, all significantly superior to placebo
This allows you and your healthcare provider to find the lowest effective dose that achieves and maintains your weight loss goals while keeping side effects tolerable
